⭐ Start off 2025 with a powerful boost to your portfolio: January’s freshest AI-picked sharesUnlock shares

Estee Lauder stock holds buy at DA Davidson, driven by sustained Clinique growth

EditorAhmed Abdulazez Abdulkadir
Published 03/09/2024, 17:58
© Reuters.
EL
-

On Tuesday, DA Davidson maintained a Buy rating on shares of Estee Lauder (NYSE:EL), with a set price target of $130.00. The firm's endorsement follows positive indicators from Ulta Beauty (NASDAQ:ULTA), which highlighted Estee Lauder's Clinique brand for its strong performance in the recent quarter.

This aligns with Estee Lauder's own report from its fourth-quarter fiscal 2024 earnings call, where it noted that Clinique had gained U.S. market share for three months straight through July.

Estee Lauder has been actively refining Clinique's marketing strategy, emphasizing the brand's dermatological heritage. This move is aimed at countering competitive pressures from L'Oreal's (OR-Paris) dermatology-focused brands that are available in standard retail outlets. The strategic marketing shift underscores Estee Lauder's adaptability in a competitive beauty and skincare marketplace.

In addition to the brand's growth, DA Davidson's report also pointed out the significance of travel retail to Estee Lauder's business, which constitutes 19% of the company's sales. The mention of travel retail is timely, considering the release of a new ranking of top travel retailers. The analyst's valuation of Estee Lauder at a $130 price target is based on a 40x multiple of the projected calendar year 2025 earnings per share (EPS) of $3.25.

Estee Lauder's stock rating and price target by DA Davidson reflect a confident outlook on the company's performance and strategic initiatives. The focus on Clinique's dermatologic credentials and the importance of travel retail to the company's revenue stream are highlighted as key factors in sustaining Estee Lauder's market position.

The analyst's reaffirmation of the Buy rating and price target demonstrates a positive expectation for Estee Lauder's continued growth, particularly as the company leverages its Clinique brand and capitalizes on its significant presence in the travel retail sector.

In other recent news, Estee Lauder's financial performance faced headwinds in Asia and travel retail, leading to a year-over-year decline in organic sales predicted for the first quarter of fiscal year 2025. DA Davidson maintained its Buy rating on the company, despite these challenges, with a price target of $130.

Meanwhile, Piper Sandler upgraded Estee Lauder's stock from Neutral to Overweight, setting a price target of $114. However, TD Cowen, Morgan Stanley (NYSE:MS), Deutsche Bank (ETR:DBKGn), and Evercore ISI all adjusted their price targets for Estee Lauder, reflecting a cautious outlook.

CEO Fabrizio Freda has announced his retirement, initiating a search for a successor. As part of its future plans, Estee Lauder intends to launch the Balmain Beauty brand, expand its luxury portfolio, and build a distribution center in Hainan.

Estee Lauder's Profit Recovery and Growth Plan (PRGP) is on track, aiming to deliver between $1.1 and $1.4 billion in net profit over fiscal year 2024 levels. However, Estee Lauder's first quarter fiscal year 2025 forecast fell short of analyst expectations, leading DA Davidson to revise its earnings per share (EPS) estimate for the company, reducing it by $1.28, or 30%, to $2.95.

InvestingPro Insights

As Estee Lauder (NYSE:EL) continues to refine its marketing strategy and capitalizes on the strong performance of its Clinique brand, InvestingPro data and tips provide additional context for investors considering the company's stock. Estee Lauder's commitment to dividend growth is highlighted by it having raised its dividend for 3 consecutive years and maintaining dividend payments for 29 consecutive years, signaling a potentially attractive aspect for income-focused investors. Additionally, the company's impressive gross profit margins, which stood at 71.66% in the last twelve months as of Q4 2024, reflect its efficiency in managing production and operational costs.

While Estee Lauder's P/E ratio is high at 84.67, suggesting a premium valuation, the company's net income is expected to grow this year, which could justify the higher earnings multiple to some investors. Notably, the stock has experienced a significant price drop over the last three months, with a 25.67% decline, and a 37.62% fall over the last six months. This could indicate a potential entry point for investors who are bullish on the company's long-term prospects and believe the market may have overreacted to short-term challenges.

InvestingPro Tips indicate that Estee Lauder operates with a moderate level of debt and has liquid assets that exceed its short-term obligations, providing a cushion for operational flexibility. For investors seeking deeper insights, there are additional InvestingPro Tips available, which can be accessed on the InvestingPro platform for Estee Lauder at https://www.investing.com/pro/EL.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.